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Even though new concepts have been introduced with regard to treatment of a vari-
ety of cancers, such as various targeted pro-drug and gene therapy approaches, systemic
anti-proliferative agents that prevent cellular DNA function are still among the most
widely used forms of anti-cancer chemotherapy. Amongst these is the general class of
anti-cancer drugs named topoisomerase (Topo) inhibitors (1). Topo I-targeted drugs (e.g.,
irinotecan) and Topo II-targeted drugs (e.g., doxorubicin), act by stabilizing the covalent
enzyme-DNA complex, thereby preventing relegation in the process (2). Increased use of
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To investigate potential prevention or attenuation of an-
ti-cancer drug induced cardiotoxicity using anti-ische-
mic drugs, a rat myoblast (H9c2) cell line was used as
our in vitro cardiac model. Irinotecan and doxorubicin
were found to be cytotoxic for the H9c2 cell line with
IC50 of 30.69 ± 6.20 and 20.94 ± 6.05 mmol L–1, respecti-
vely. 5-Flurouracil and cladribine were not cytotoxic and
thus IC50 could not be calculated. When 100 mmol L–1 do-
xorubicin was incubated for 72 hours with 50 mmol L–1
diltiazem, 100 mmol L–1 dexrazoxane and 100 mmol L–1
losartan, respectively, there was a 58.7 ± 10.2, 52.2 ± 11.7
and 44.7 ± 5.4 % reduction in cell death. When 200 mmol
L–1 irinotecan was incubated for 72 hours with 100 mmol
L–1 dexrazoxane, losartan and diltiazem, respectively, a
27.7 ± 6.9, 25.6 ± 5.1, and 19.1 ± 2.3 % reduction in cell
death was observed. Our data suggests that losartan and
diltiazem were as effective as dexrazoxane in protecting
the cells against irinotecan- and doxorubicin-induced
cell toxicity. These findings offer potential uses of anti-
-ischemic drugs for ablation of cytotoxicity in response
to mitochondrial injury, thereby improving patient out-
comes and reducing health-care costs.
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irinotecan and doxorubicin poses an increased risk of cytotoxicity, resulting from car-
diomyocyte apoptosis, myocardial fibrosis, leading to cardiomyopathy, arrhythmias and
congestive heart failure (3).
Anthracyclines are highly potent antineoplastic agents for numerous hemopoietic
and solid tumors (4). However, their use is limited due to serious cytotoxicity, that has
been proven to be fatal. Hence, there is a need for a method that could reduce the cy-
totoxicity of these agents, thus increasing their use for a larger patient population. The
precise mechanism how these chemotherapeutic agents induce cytotoxicity is still un-
known, but many theories have been presented, such as the notion that anthracyclines
intercalate DNA and promote free radical synthesis which causes tissue damage. Nu-
merous methods have been suggested for effectively blocking doxorubicin-induced cy-
totoxicity. The suggested methods include inhibition of endocanabiniods, administration
of antioxidants and scavengers of peroxynitrite, iron chelating agents and glutamate,
use of agents such as erythropoietin or granulocyte stimulating agents, targeted disrup-
tion of p53 activity by global gene knockout, chemical inhibition, or cardiomyocyte spe-
cific ablation of p53 (5). Another possible method to reduce cytotoxicity is the concept of
co-administration of cytoprotectants with the chemotherapeutic agent. This may impro-
ve patient outcomes, minimize harm and decrease health care costs. In this study, we in-
vestigated the use of cytoprotective drugs in the presence of cardiocytotoxic anti-cancer
drugs hoping to reduce cell death.
EXPERIMENTAL
Chemicals
Doxorubicin, dexrazoxane, 5-flurouracil, cladribine, and [3-(4,5-dimethylthiazol-2-
-yl)-2,5-diphenyltetrazolium bromide, MTT] were purchased from Sigma Chemical Co.
(USA). Diltiazem, losartan and irinotecan were provided by their developers from Cana-
da Sanofi-Aventis Canada Inc., Merk-Frosst Canada Ltd. and Pfizer Canada Inc., respec-
tively. DMEM/F12 1/1, streptomycin (100 mg mL–1), penicillin (100 IU mL–1), physiologi-
cal saline, trypsin-EDTA and fetal bovine serum (FBS) were from Invitrogen (Canada).
Cell culture
Rat myoblast (H9c2) cell line was obtained from Cedarlane (Canada). The cells were
cultured according to the supplier’s protocol and sub-cultured every other day with
DMEM/F12 supplemented with 10 % FBS at 37 °C in a humidified environment (5 %
CO2/95 % O2). During passaging, the cells were trypsinized with 0.25 % trypsin-EDTA
for not more than 15 min.
Cytotoxicity assay
Cytoprotection studies were performed on confluent cells in 96-well plates. Chemo-
therapeutic agents and anti-ischemia drugs were added into the wells and cells were in-
cubated for 72 hours. Concentrated solutions of test compounds were used to avoid up
to 10 % dilution of the media supplement used for feeding the cells (10 % FBS in
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DMEM/F12). Cell toxicity was quantified using a MTT assay. Cells grown without cy-
toprotective drugs served as negative controls while cells grown with dexrazoxane, a
clinically approved cytoprotectant, served as a positive control. Cell survival was ex-
pressed using simple percentages and IC50.
In order to measure the cytotoxicity of anti-cancer drugs, the H9c2 cells were pre-in-
cubated with various concentrations of doxorubicin or irinotecan for 72 hours. Prelimi-
nary studies involving incubation for 12, 24, 48 and 72 hours, were performed and sho-
wed that incubation for 72 hours gave the most reproducible results and therefore it was
used for subsequent studies.
MTT stock solution was made by dissolving 5 mg of thiazolyl blue tetrazolium bro-
mide in 1 mL of PBS solution. An aliquot of the stock solution (10 mL) was added to each
well after the test compounds had been incubated at 37 °C in a humidified environment
(5 % CO2/95 % O2) for 4 hours to allow the MTT to be converted to colored tetrazolium
dye. The medium was then removed and formazan salt crystals were dissolved in 200
µL dimethyl sulfoxide. The absorbance of the wells was measured at 560 nm using an
ELISA plate reader (BioTek Synergy HT, Biotek Instruments, USA).
Fluroescence microscopy
The rat myoblast (H9c2) cell line was suspended in a DMEM/F12 supplemented
with 10 % FBS and seeded on a 6-well plate. Stock solutions of test compounds (doxo-
rubicin, irinotecan) were added to the medium, bringing the well volume up to 2 mL
containing 100 mmol L–1 of each chemotherapeutic agent. The cells were then incubated
at 37 °C in a humidified environment (5 % CO2/95 % O2) for 72 hours with the anti-
-ischemic/cytoprotectant or a control involving only the chemotherapeutic agent. At the
end of the incubation period, epifluorescence microscopy was performed using a Zeiss
Axiovert 10 microscope with oil immersion objectives (Carl Zeiss Ltd., USA). Fluores-
cence excitation was at 488 nm and emission at 520 nm.
Data analyses
Unless stated otherwise, all experiments were performed in 4 replicates and data
were presented as mean ± SD. IC50 was determined using non-liner regression with
Graphpad Prism (San Diego, CA, USA). Change in cell viability was calculated and ex-
pressed as percentage. These changes were compared for statistical significance using
the analysis of variance (ANOVA) followed by post-test analysis and were considered
significant at p < 0.05.
RESULTS AND DISCUSSION
Estimation of cardiac cytotoxicity of doxorubicin, irinotecan, 5-flurouracil
and cladribine in H9c2 cells
The first part of the study involved an estimation of cytotoxicity of selected
chemotherapeutic drugs in H9c2 cells. In order to measure the cytotoxicity of anticancer
drugs, the H9c2 cells were pre-incubated with various concentrations of doxorubicin or
irinotecan for 72 hours. Preliminary studies involving incubation for 12, 24, 48 and 72
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hours, were performed and showed that incubation for 72 hours gave most reproducible
results and it was therefore used for subsequent studies (Fig. 1). Consistent with previ-
ous studies (6), we observed decreased cell viability with increasing concentration of do-
xorubicin using MTT and propidium assay. After 72 hours of incubation with doxoru-
bicin at varying concentration, the half maximal inhibitory concentration (IC50) of doxo-
rubicin was calculated to be 20.94 ± 6.05 mmol L–1 (Fig. 2). Similarly, the IC50 of irino-
tecan was 30.69 ± 6.19 mmol L–1 (Fig. 2). The IC50 of 5-flurouracil and cladribine could
not be calculated since the target range tested did not have any toxic effects on the H9c2
cell line (Fig. 1). Therefore, only doxorubicin and irinotecan were used in subsequent
cytoprotection studies.
Once administered, irinotecan is activated as a result of hydrolysis in the liver to
SN-38, a Topo-I inhibitor. The SN-38 compound is then inactivated by uridine diphos-
phate glucoronosyltransferase 1A1 in the hepatic tissue to the corresponding glucuro-
nide (7). However, unlike hepatocytes, most other cells in the body are incapable of de-
toxifying SN-38 through glucoronidation, resulting in the seen cytotoxicity (8). The
inhibitory effect of Topo-II by doxorubicin is well established. Another mechanism for
cellular toxicity is that doxorubicin is also able to undergo redox reaction in the mito-
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Fig. 1. Dose response curves for doxorubicin, irinotecan, cladribine, and 5-flurouracil. Data are ex-
pressed as mean percent of cell survival ± SD (n = 4).






































Fig. 2. Effect of incubation time on: a) doxorubicin and b) irinotecan.
chondria, where it is reduced via NADH dehydrogenase, forming a semiquinone com-
pound (9). The semiquinone compound is then oxidized back to its original structure
once its electron is transferred to an oxygen, thus generating a reactive oxygen species
(ROS) including hydrogen peroxide and hydroxyl radicals. The generated superoxides
then react with nitric oxides in the surrounding tissue generating a reactive nitrogen
species (RNS) (5). The build-up of ROS/RNS in cells can cause DNA damage, activation
of poly ADP ribose polymerase, up-regulation of redox sensitive transcription factors
(p53 and NF-kB), and an increase in mitochondrial permeability and apoptosis (10).
Cytoprotective effects of dexrazoxane, losartan and diltiazem against
toxicities induced by doxorubicin and irinotecan in H9c2 cells
After determining the IC50 for cytotoxicity of doxorubicin and irinotecan in our as-
say, the protective effect of the anti-ischemia drugs losartan and diltiazem was assessed.
Our first approach was to determine the concentration range that will be used for the
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Fig. 3. Effect of dexrazoxane, diltiazem, and losartan cconcentrations on irinotecan-induced cytoto-
xicity in H9c2 cells.
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Fig. 4. Effect of dexrazoxane, diltiazem, and losartan concentrations on doxorubicin-induced cyto-
toxicity in H9c2 cells.
cytoprotection studies. This was achieved by investigating the effect of 10, 50 and 100
mmol L–1 of dexrazoxane, losartan and diltiazem on doxorubicin and irinotecan-induced
cytotoxicity (Figs. 3 and 4). The observed effect was not evident at the 10 mmol L–1 con-
centration. Therefore in subsequent cytoprotection studies only doxorubicin and irino-
tecan were used using dexrazoxane as control. It was evident that co-incubation of 50
mmol L–1 diltiazem, 100 mmol L–1 dexrazoxane, and 100 mmol L–1 losartan was able to di-
minish the effects of doxorubicin on H9c2 cells in lower concentrations, while still main-
taining higher than 50 % viability at higher concentrations (Fig. 5). In fact, when
doxorubicin was incubated for 72 h with 50 m mol L–1 of diltiazem, there was a 58.7 ±
10.2 % reduction in cell death. Similarly, co-incubation of doxorubicin for 72 h with 100
m mol L–1 dexrazoxane resulted in 52.2 ± 11.7 % reduction of cell death. Although less ef-
fective in comparison with diltiazem and dexrazoxane, co-incubation with 100 mmol L–1
of losartan also resulted in 44.7 ± 5.4 % reduction in cell death. On the other hand, the
anti-ischemia and cytoprotective effects of dexrazoxane, losartan, and diltiazem were
less effective against cytotoxicity from irinotecan compared to the effect observed in re-
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Fig. 5. Effect of anti-ischemia drugs, losartan and diltiazem, in the presence of doxorubicin after 72 h
of incubation.
























Fig. 6. Effect of anti-ischemia agents on cell survival when
sponse to doxorubicin (Fig. 6). Co-incubation of irinotecan with 100 mmol L–1 of dex-
razoxane, losartan or diltiazem reduced cell death by 27.7 ± 6.9, 25.0 ± 5.1, 19.1 ± 2.3 %,
respectively.
Fluorescence microscopy allowed visualization of the cytotoxic effect of doxorubi-
cin, compared to the control H9c2 cells (Fig. 7a). There was a significant reduction in
H9c2 cell viability after incubation with 100 mmol L–1 doxorubicin for 72 h (Fig. 7b). Al-
though not as potent as doxorubicin (Fig. 7c), incubation of H9c2 cells with 100 mmol L–1
of irinotecan for 72 h resulted in significant reduction in viable cells. However, co-incu-
bation of the cells with 100 mmol L–1 of irinotecan along with 100 mmol L–1 of dexrazo-
xane (Fig. 7d), diltiazem (Fig. 7e), and losartan (Fig. 7f) clearly demonstrated the cyto-
protective properties of these drugs. Surprisingly, diltiazem and losartan proved to be
more cytoprotective than our control (dexrazoxane) in H9c2 cells against doxorubicin-
-induced toxicity.
Just like with most successful drugs, discovery of the cytoprotective effect of dex-
razoxane was completely serendipitous. The cytoprotective effects of dexrazoxane, in
the presence of doxorubicin, have been well established in animal species (11) and hu-
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Fig. 7. Fluorescence visualization of cytoprotective effect of dexrazoxane, diltiazem and losartan
against doxorubicin-induced toxicity in H9c2 myoblast cell line and potential cytotoxicity: a) control
(PBS), b) irinotecan and c) doxorubicin. Cells incubated with doxorubicin in the presence of: d) dexra-
zoxane, e) diltiazem and f) losartan.
mans (12). Furthermore, clinical trials have revealed that the cytoprotection of dexrazo-
xane does not interfere with the anti-tumor effects of doxorubicin, and therefore to this
day dexrazoxane serves as one of the best cytoprotective drugs against doxorubicin (13).
The hydroxyl radical that makes up the ROS is a highly reactive species that can cause
lipid peroxidation, oxidative damage to DNA, and eventual cell death (14). The cyto-
protective capability of dexrazoxane is due to its high affinity for LMW-Fe+2, which are
produced due to the formation of doxorubicin-iron complexes and the subsequent pro-
duction of ROS and hydroxyl radicals (15). The iron-chelating capability of dexrazoxane
was quite evident in the doxorubicin treated H9c2 cells, since it was capable of dimin-
ishing the effects of doxorubicin at lower and higher concentrations, as seen in Fig. 5. Al-
though cell death was reduced in the irinotecan treated H9c2 cells, the cytoprotective ef-
fects of dexrazoxane were not as potent as seen in the doxorubicin treated group, thus
suggesting that the toxicity of irinotecan may be due to other cellular mechanisms in ad-
dition to that attributed to LMW-Fe+2 seen during the formation of doxorubicin-iron
complexes which lead to subsequent production of ROS and hydroxyl radicals.
Losartan was the first non-peptide selective angiotensin II receptor blocker appro-
ved for clinical use. It is metabolized by cytochrome P450 to the more potent EXP3174
metabolite (16). In addition to its antihypertensive property, losartan has also been
shown to have anti-fibrotic capabilities of reducing incidence of cardiac and renal fibro-
sis. Losartan has been suggested to suppress the effects of transforming growth factor-b1
(TGF-b1) (17). TGF-b1 is a cytokine that plays a veriety of roles in cellular processes such
as proliferation, differentiation, apoptosis, fibrosis and tumorgenesis (18). Previous stud-
ies have shown a significant increase in TGF-b1 and 2 receptor expression in doxorubi-
cin induced glomerular toxicity (19). Furthermore, other studies, investigating the cyto-
protective effects of doxorubicin-induced rat heart failure, suggested that the protective
effects of losartan in doxorubicin-induced heart failure could be due to regulation of cir-
culating angiotensin (1–7) and myocardial angiotensin (1) receptor expression (20). We
were also able to show similar findings in our doxorubicin and irinotecan treated H9c2
cells. It is evident from Figs. 5 and 6 that 100 mmol L–1 of losartan is capable of signifi-
cantly diminishing doxorubicin and irinotecan induced toxicity, which could be due to
its ability to reduce the effects of TGF-b1 or its expression.
Diltiazem is a benzothiazepine calcium channel blocker with special selectivity for
vascular calcium channels (21). Contradictory to our findings, diltiazem seems to enhan-
ce the cytotoxicity of doxorubicin in Ehrlich ascites carcinoma cells (22). A mode of do-
xorubicin’s cytotoxicity is believed to be due to induction of calcium cycling in cardiac
mitochondria. In fact, evidence has been provided by Revis and Marusic (23) and Bach-
man and Zbinden (24) that doxorubicin reduces the net amount of calcium (Ca2+) accu-
mulation in the mitochondria. Further, Ca2+ influx increase in mitochondria could lead
to loss of mitochondrial membrane potential, causing cytochrome-c release and subse-
quent caspase activation (25). Interestingly, the mitochondrial shift towards a more oxi-
dized state took place parallel with significant mitochondrial depolarization that occur-
red concurrently with increased mitochondrial Ca2+ levels (26). It has been well esta-
blished that the increase in Ca2+ levels and drop in mitochondrial membrane potential
are associated with the production of ROS and that both steps occur prior to the induc-
tion of mitochondrial permeability transition and subsequent cell death (27). We have
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shown that by blocking the calcium channels of H9c2 cells using diltiazem one can sig-
nificantly reduce the influx of extra-cellular Ca2+, which minimizes the detrimental ef-
fects of doxorubicin.
Diltiazem was also the most potent drug that reduced cell death when co-adminis-
tered with irinotecan. Although there has been no report of an increase in intracellular
Ca2+ levels from irinotecan, our findings suggest that similarly to doxorubicin, irinote-
can may also increase intracellular Ca2+ levels. From the three cytoprotective drugs used
in co-treatment with irinotecan, diltiazem was the most effective in diminishing irinote-
can-induced H9c2 cell death. Perhaps future studies could focus on Ca2+ levels of cells
after treatment with irinotecan to determine whether there is a Ca2+ influx or increase
associated with irinotecan.
CONCLUSIONS
We investigated the effects of anti-ischemia drugs, losartan and diltiazem, as well as
dexrazoxane, which have been shown to provide long-term cytoprotection without af-
fecting the efficacy of doxorubicin (28). Dose response experiments for cytoprotective ef-
fect were performed using rat myoblast (H9c2) cells in the presence of doxorubicin and
irinotecan, and the listed cytoprotective and anti-ischemia drugs. We chose H9c2 due to
its availability and the fact that it is of cardiac origin, and has been previously used to
investigate doxorubicin-induced hypertrophy and cardiac apoptosis (29). In summary,
our results suggest that the use of cytoprotective or anti-ischemia drugs (dexrazoxane,
losartan and diltiazem) with cytotoxic anticancer drugs (doxorubicin and irinotecan)
could have an attenuating effect on cardiac toxicity. Use of these protective agents ap-
peared more effective for doxorubicin compared to irinotecan treated H9c2 cells. It is im-
perative to note that these drugs can only ablate one or two detrimental effects of these
cardiotoxic anticancer drugs, and future studies should focus on therapies involving dif-
ferent combinations of drugs that target different detrimental effects. Combined use of
cytoprotective or anti-ischemia drugs in cancer therapies, particularly with those known
to cause adverse cardiac events, could improve patient compliance, reduce mortality
and healthcare costs in the future.
Acknowledgments. – Funding was provided by the Pharmacy Endowment Fund, Dalhousie
University.
REFERENCES
1. W. A. Denny, Emerging DNA topisomerase inhibitors as anticancer drugs, Expert Opin. Emerg.
Drugs 9 (2004) 105–133; DOI: 10.1517/eoed.9.1.105.32948.
2. L. F. Liu, DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem. 58 (1989) 351–
375; DOI: 10.1146/annurev.bi.58.070189.002031.
3. G. Takemura and H. Fujiwara, Doxorubicin-induced cardiomyopathy from the cardiotoxic
mechanisms to management, Prog. Cardiovasc. Dis. 49 (2007) 330–352; DOI: 10.1016/j.pcad.2006.
10.002.
501
T. Feridooni et al.: Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast
cell line, Acta Pharm. 63 (2013) 493–503.
4. S. Hitchcock-Bryan, R. Gelber, J. R. Cassady and S. E. Sallan, The impact of induction anthra-
cycline on long-term failure-free survival in childhood acute lymphoblastic leukemia, Med.
Pediatr. Oncol. 14 (1986) 211–215; DOI: http://dx.doi.org/10.1002/mpo.2950140405.
5. T. Feridooni, A. Hotchkiss, S. Remley-Carr, Y. Saga and K. B. S. Pasumarthi, Cardiomyocyte
specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and asso-
ciated cytoskeletal changes, PLoS ONE 6 (2011) e22801; DOI: 10.1371/journal.pone.0022801.
6. X. Z. Han, S. Gao, Y. N. Cheng, Y. Z. Sun, W. Liu, L. L. Tang and D. M. Ren, Protective effect of
naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyo-
cytes, Biosci. Trends 6 (2012) 19–25; DOI: 10.5582/bst.2012.v6.1.19.
7. B. Glimelius, Benefit-risk assessment of irinotecan in advanced colorectal cancer, Drug Saf. 28
(2005) 417–433; DOI: http://dx.doi.org/10.2165/00002018-200528050-00005.
8. J. Weekes, A. K.-Y. Lam, S. Sebesan and Y.-H. Ho, Irinotecan therapy and molecular targets in
colorectal cancer: a systemic review, World J. Gastroenterol. 15 (2009) 3597–3602; DOI: http://dx.
doi.org/10.3748/wjg.15.3597.
9. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, Anthracyclines: molecular advan-
ces and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev.
56 (2004) 185–229; DOI: 10.1124/pr.56.2.6.
10. R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair and T. D. Oberley, Mito-
chondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin
(Adriamycin)?, Antioxid. Redox Signal. 9 (2007) 1001–1008; DOI: 10.1089/ars.2007.1632.
11. E. H. Herman and V. J. Ferrans, Amelioration of chronic anthracycline cardiotoxicity by ICRF-
-187 and other compounds, Cancer Treat Rev. 14 (1987) 225–259; DOI: 10.1016/0305-7372(87)
90011-9.
12. S. M. Swain, F. S. Whaley, M. C. Gerber, M. S. Ewer, J. R. Bianchine and R. A. Gams, Delayed ad-
ministration of dexrazoxane provides cardioprotection for patients with advanced breast cancer
treated with doxorubicin-containing therapy, J. Clin. Oncol. 15 (1997) 1333–1340.
13. S. M. Swain and P. Vici, The current and future role of dexrazoxane as a cardioprotectant in
anthracycline treatment: expert panel review, J. Cancer Res. Clin. Oncol. 130 (2004) 1–7; DOI: 10.
1007/s00432-003-0498-7.
14. M. S. Wolin, Interactions of oxidants with vascular signaling systems, Arterioscl. Throm. Vas.
Biol. 20 (2000) 1430–1442; DOI: 10.1161/01.ATV.20.6.1430.
15. D. B. Sawyer, R. Fukazawa, M. A. Arstall and R. A. Kelly, Daunorubicin-induced apoptosis in
rat cardiac myocytes is inhibited by dexrazoxane, Circ. Res. 84 (1999) 257–65; DOI: 10.1161/01.
RES.84.3.257.
16. J. Bierau, R. Leen, A. H. van Gennip, H. N. Caron and A. B. P. van Kuilenburg, Determination of
the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using re-
versed-phase high performance liquid chromatography; Identification of a novel metabolite of
2-chlorodeoxyadenosine, J. Chromatogr. B 805 (2004) 339–346; DOI: 10.1016/j.jchromb.2004.03.
036.
17. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher and R. K. Jain, Losartan inhibits collagen
I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, Proc. Natl.
Acad. Sci. USA 108 (2011) 2909–2914; DOI: 10.1073/pnas.1018892108.
18. C. E. Runyan, H. W. Schnaper and A.-C. Poncelet, The role of internalization in transforming
growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SA-
RA) and Smad2-dependent signaling in human mesangial cells, J. Biol. Chem. 280 (2005) 8300–
8308; DOI: 10.1074/jbc.M407939200.
19. K. Tamaki, S. Okuda, T. Ando, T. Iwamoto, M. Nakayama and M. Fujishima, TGF-beta 1 in glo-
merulosclerosis and interstitial fibrosis of adriamycin nephropathy, Kidney Int. 45 (1994) 525–
536.
502
T. Feridooni et al.: Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast
cell line, Acta Pharm. 63 (2013) 493–503.
20. W. Zong, X. Yang, X. Chen, H. Huang, H. Zheng, X. Qin, Y. Yong, K. Cao, J. Huang and X. Lu,
Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in
adriamycin-induced rat heart failure, Acta Pharmacol. Sin. 32 (2011) 1345–1350; DOI: 10.1038/
aps.2011.96.
21. L.-Y. Chiu, J.-L. Ko, Y.-J. Lee, T.-Y. Yang, Y.-T. Tee and G.-T. Sheu, L-type calcium channel blo-
ckers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1
expression in human lung cancer cell lines, Toxicol. Lett. 192 (2010) 408–418; DOI: 10.1016/j.
toxlet.2009.11.018.
22. O. A. Al-Shabanah, A. M. Osman, M. M. Al-Harbi, A. M. Al-Bekairi, N. M. Al-Gharably and S.
A. Aziz, Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in Ehrlich as-
cites carcinoma cells, Chemotherapy 41 (1995) 368–377; DOI: 10.1159/000239369.
23. N. W. Revis and N. Marusi}, Effects of doxorubicin and its aglycone metabolite on calcium se-
questration by rabbit heart, liver, and kidney mitochondria, Life Sci. 25 (1979) 1055–1063; DOI:
10.1016/0024-3205(79)90591-5.
24. E. Bachmann and G. Zbinden, Effect of doxorubicin and rubidazone on respiratory function
and Ca2+ transport in rat heart mitochondria, Toxicol. Lett. 3 (1979) 29–34; DOI: 10.1016/0378-
4274(79)90103-6.
25. X. Tan, D.-B. Wang, X. Lu, H. Wei, R. Zhu, S.-S. Zhu, H. Jiang and Z.-J. Yang, Doxorubicin in-
duces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation
factor 5A, Biol. Pharm. Bull. 33 (2010) 1666–1672; DOI: 10.1248/bpb.33.1666.
26. A. V. Kuznetsov, R. Margreiter, A. Amberger, V. Saks and M. Grimm, Changes in mitochondrial
redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubi-
cin-induced cell death, Biochim. Biophys. Acta 1813 (2011) 1144–1152; DOI: 10.1016/j.bbamcr.
2011.03.002.
27. F. De Oliveira, C. Chauvin, X. Ronot, M. Mousseau, X. Leverve and E. Fontaine, Effects of per-
meability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in
K562 cells, Oncogene 25 (2006) 2646–2655; DOI: 10.1038/sj.onc.1209293.
28. S. E. Lipshultz, R. E. Scully, S. R. Lipsitz, S. E. Sallan, L. B. Silverman, T. L. Miller, E. V. Barry, B.
L. Asselin, U. Athale, L. A. Clavell, E. Larsen, A. Moghrabi, Y. Samson, B. Michon, M. A. Scho-
rin, H. J. Cohen, D. S. Neuberg, E. J. Orav and S. D. Colan, Assessment of dexrazoxane as a
cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia:
long-term follow-up of a prospective, randomised, multicentre trial, Lancet Oncol. 11 (2010)
950–961; DOI: 10.1016/S1470-2045(10)70204-7.
29. K. E. Merten, Y. Jiang, W. Feng and Y. J. Kang, Calcineurin activation is not necessary for Doxo-
rubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phospho-
inositide 3-kinase-Akt pathway, J. Pharmacol. Exp. Ther. 319 (2006) 934–940; DOI: 10.1124/jpet.
106.108845.
503
T. Feridooni et al.: Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast
cell line, Acta Pharm. 63 (2013) 493–503.
